Cardinal Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cardinal Health, Inc.
Japan Readies One-Off Price Cuts For Big Sellers
Japanese regulatory authorities have announced a set of additional reimbursement price cuts for selected products in August, under which Novartis’s heart failure drug Entresto will see its price slashed by 15%. A batch of other newly approved drugs has also been priced.
Finance Watch: Biopharma Stocks Attempt An April Rebound
Public Company Edition: With the XBI up more than 9% in April, a few follow-on offerings –$23m to support Gamida Cell’s small product launch and $500m to fund Vaxcyte’s large clinical trial program – have made it to market. Also, China’s CytoMed launched the sixth biopharma IPO in the US this year.
Aldeyra All Set For Double Date With The FDA
The US agency is reviewing two of the US biotech’s drug with decisions expected on its methotrexate product for ocular lymphoma by June and on the dry eye drug reproxalap in November, as Aldeyra mulls its marketing strategy for both.
FY2022: Medtech Innovators Exchange Top 10 Placings
The leading global medtechs’ fiscal 2022 revenue reports are all in: Abbott Laboratories moved above Medtronic in MAT medtech revenues, while Philips Healthcare and Stryker finished the year with strong quarters and Roche dropped a few places.
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Home Infusion
- Hospitals, Nursing Homes, Institutions
- Pharmacy Services, PBMs
- Controlled Release
- Drug Delivery
- Other Names / Subsidiaries
- Allegiance Healthcare Corporation
- Cordis Corporation
- Innovative Therapies, naviHealth
- The Harvard Drug Group
- VIASYS Healthcare
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.